Anlon Healthcare Quarterly Results for Trading Insights
In Mar 2026, Anlon Healthcare (AHCL) reported revenue ₹51 Cr and net profit ₹11 Cr — revenue +4.1% YoY. For annual financials, live price and key ratios, visit Anlon Healthcare share price screener.
AHCL Quarterly Results — Revenue, Profit & EPS Highlights
Anlon Healthcare latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with Anlon Healthcare value estimation to assess whether the stock is under or overvalued.
- Revenue of ₹51 Cr in Mar 2026 (+4.1% vs Mar 2025, +4.1% vs Mar 2025)
- Net Profit of ₹11 Cr in Mar 2026 (-35.3% vs Mar 2025, -35.3% vs Mar 2025)
- EBITDA of ₹15 Cr in Mar 2026 (-11.8% vs Mar 2025)
- Operating Margin of 30.0% in Mar 2026 (-5.0pp vs Mar 2025)
- Earnings Per Share of ₹2.33 in Mar 2026 (-54.8% vs Mar 2025)
Anlon Healthcare Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AHCL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Mar 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 51 | 49 | 36 | 4.1% | 4.1% |
| Net Profit (₹ Cr) | 11 | 17 | 5 | - | - |
| EBITDA (₹ Cr) | 15 | 17 | 13 | - | - |
| EPS (₹) | 2.33 | 5.15 | 1.13 | - | - |
| Operating Margin (%) | 30.0% | 35.0% | 35.0% | - | - |
AHCL Share Price Trend — 1-Year Movement Across Quarterly Results
Anlon Healthcare 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Anlon Healthcare share price performance to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AHCL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Anlon Healthcare latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.9 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.9 |
|
Divis Laboratories
Mar 2026 |
₹175,434.91 Cr | 6787.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 239.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4457.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 387.2 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1085.5 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
|
Cipla
Mar 2026 |
₹109,195.79 Cr | 1415.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.1 |
All amounts in ₹ Crores